TrialBlood2013

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Michael Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.